| Theme | The State of the Art in Chemotherapy for Gastrointestinal Cancer | |
|---|---|---|
| Title | Chemotherapy for Gastric Cancer：Determining Standard Regimensfor Individual Clinical Setting | |
| Publish Date | 2011/06 | |
| Author | Masahiro Gotoh | Cancer Chemotherapy Center, Osaka Medical College |
| Author | Hiroya Takiuchi | Cancer Chemotherapy Center, Osaka Medical College |
| [ Summary ] | According to the results of phase III trials, S-1 plus CDDP has been accepted as the first-line standard regimen in Japan. On the other hand, trastuzumab in combination with chemotherapy may be considered to be a new standard option for patients with HER2-positive gastric cancer. However, there is no standard regimen for patients with massive malignant ascites and／or poor oral intake. | |